Trial
NCT02269436
A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Newron Sweden AB
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis
Intervention
sNN0029 infusion solution
Why stopped
Issues with development and supply of infusion system for delivery of IMP. Lack of favorable benefit risk ratio in sNN0029-003 study (review of interim data).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-01-27